secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2026-04-14T23:59:59+00:00
Accession:  0001193125-26-154927
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos: Phase 2 HBV interim – DSMB ups HBeAg- sample size to 100; FDA Fast Track granted
--------------------------------------------------------------------------------

- DSMB recommended increasing HBeAg- cohort from 74 to 100 participants to optimize power; futility criteria not met.
- Study drugs well-tolerated; no viral breakthrough; safety data reviewed across all 174 enrolled participants.
- FDA granted Fast Track Designation for pevifoscorvir sodium based on 96-week Phase 1 data.
- Topline data from B-SUPREME study remains on track for 2027; enrollment in HBeAg- cohort expected by H2 2026.
- Aligos remains blinded to participant-level data; 103 enrolled in HBeAg+ cohort (Part 1a).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000119312526154927/0001193125-26-154927-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000119312526154927/d107028d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-154927

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer